Clinical trial
FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant…
NCT00104884 · ECOG-ACRIN Cancer Research Group, Other · Terminated
Key facts
| NCT number | NCT00104884 |
|---|---|
| Title | FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma |
| Official title | Phase II Trial of Depsipeptide (NSC 630176) in Advanced Malignant Melanoma |
| Lead sponsor | ECOG-ACRIN Cancer Research Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Malignant Melanoma, Melanoma |
| Intervention type | Drug |
| Interventions | Depsipeptide |
| Enrollment | 4 |
| Start date | Oct 4, 2005 |
| Primary completion | May 1, 2006 |
| Completion | Mar 1, 2009 |
| First posted | Mar 4, 2005 |
| Last update posted | Jun 28, 2023 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: